Qyuns Therapeutics Co., Ltd. Class H (HK:2509)
:2509
Want to see HK:2509 full AI Analyst Report?
2509 Analyst Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
2509 Stock 12 Month Forecast
Average Price Target
HK$35.18
▲(23.08% Upside)
| Highest Price TargetHK$37.35 | Average Price TargetHK$35.18 | Lowest Price TargetHK$33.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Unknown Analyst
TFI Asset ManagementNot Ranked
TFI Asset Management
HK$40.25
Buy
40.83%
Upside
Reiterated
09/29/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Unknown Analyst
TFI Asset ManagementNot Ranked
TFI Asset Management
HK$40.25
Buy
40.83%
Upside
Reiterated
09/29/25
Best Analysts Covering Qyuns Therapeutics Co., Ltd. Class H
3 Months
Success Rate
0/2 ratings generated profit
Average Return
-2.35%
Copying Google Health Care HK's trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -2.35% per trade.
1 Year
Success Rate
0/2 ratings generated profit
Average Return
-2.35%
Copying Google Health Care HK's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -2.35% per trade.
2 Years
Success Rate
0/2 ratings generated profit
Average Return
-2.35%
Copying Google Health Care HK's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -2.35% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
2509 Analyst Recommendation Trends
Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
1
3
3
2
Buy
1
1
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
1
2
3
3
2
Each month's total comprises the sum of three months' worth of ratings.
2509 Financial Forecast
2509 Stock Forecast FAQ
What is HK:2509’s average 12-month price target, according to analysts?
Based on analyst ratings, Qyuns Therapeutics Co., Ltd. Class H’s 12-month average price target is 35.18.
What is HK:2509’s upside potential, based on the analysts’ average price target?
Qyuns Therapeutics Co., Ltd. Class H has 23.08% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Qyuns Therapeutics Co., Ltd. Class H a Buy, Sell or Hold?
Qyuns Therapeutics Co., Ltd. Class H has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
What is Qyuns Therapeutics Co., Ltd. Class H’s share price target?
The average share price target for Qyuns Therapeutics Co., Ltd. Class H is 35.18. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is HK$37.35 ,and the lowest forecast is HK$33.00. The average share price target represents 23.08% Increase from the current price of HK$28.58.
The highest analyst share price target is HK$37.35 ,and the lowest forecast is HK$33.00. The average share price target represents 23.08% Increase from the current price of HK$28.58.
What do analysts say about Qyuns Therapeutics Co., Ltd. Class H?
Qyuns Therapeutics Co., Ltd. Class H’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
How can I buy shares of Qyuns Therapeutics Co., Ltd. Class H?
To buy shares of HK:2509, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.